Aim: To study efficacy of treating patients with acute coronary syndrome (ACS) without ST segment elevation (STSE) with platelet dysaggregation drugs (aspirin, cardiomagnil, clopidogrel).
Material and methods: 78 ACS without STSE were randomized into five groups: group 1 patients (n = 17) received no dysaggregants; patients of group 2 (n = 26) received aspirin in the dose 250 mg on the day of admission and then 125 mg/day; group 3 was given cardiomagnil (150 mg on the day of admission and then 75 mg/day, n = 17); group 4--clopidogrel 75 mg/day (n = 7); group 5--combination of clopidogrel 75 mg/day with cardiomagnil 75 mg/day (n = 11). All the patients were administered fraxiparin 86 IU/kg sc each 12 hours for 5-8 days.
Results: Group 1 patients showed platelet hyperaggregation, platelet aggregation decreased in groups 2, 3 and 4 (6 patients of group 1 were resistant to aspirin). The highest antiaggregation effect was achieved in group 5.
Conclusion: Control over antiaggregation treatment in patients with ACS without STSE by monitoring of platelet function open broad opportunities for selection of effective individual therapy.